News
Novocure to Participate in the 38th Annual J.P. Morgan Healthcare Conference
Novocure (NASDAQ: NVCR) will participate in the 38th Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2020, in San Francisco. William Doyle, Novocure’s Executive Chairman, will speak
QIAGEN Concludes Strategic Alternatives Review; Decides to Focus on Stand-Alone Business Strategy to Drive Future Value Creation
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) (“QIAGEN” or the “Company”) today announced that it has concluded the previously announced review of potential strategic alternatives, and
QIAGEN beendet Gespräche zur Sondierung möglicher strategischer Alternativen und beschließt Fokussierung auf eigenständige Strategie zur zukünftigen Wertschöpfung
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) („QIAGEN“ oder die „Gesellschaft“) teilte heute mit, dass die Gesellschaft die zuvor veröffentlichte Überprüfung potentieller strategischer
Intra-Cellular Therapies: Nächster Volltreffer von BB Biotech!
Bereits vor wenigen Tagen hatte ich hier bei sharedeals.de über die Forschungserfolge sowie dem damit verbundenen Kurssprung in der Aktie von Myovant Sciences berichtet. Heute nun hat die Schweizer
Sensorion Announces Positive Data Safety Monitoring Board Review of Phase 2 Trial for SENS-401 in Sudden Sensorineural Hearing Loss
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotech company which specializes in the development of novel therapies to restore, treat and prevent
Stoke Therapeutics Added to NASDAQ Biotechnology Index
Stoke Therapeutics, Inc. (Nasdaq:STOK), a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression, today
Sangamo Announces Early Completion of Transfer to Pfizer of SB-525 Hemophilia A Gene Therapy IND and an Earned $25 Million Milestone Payment
Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced today the completion of the transfer to Pfizer of the SB-525 Hemophilia A gene therapy Investigational New Drug application (IND). Pfizer is
Sensorion Announces €5.6m Non-Dilutive Funding to Support SENS-401 Phase 2 Study in Sudden Sensorineural Hearing Loss; French Ministry of Armed Forces to Participate in the Study
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN / PEA-PME eligible) a pioneering clinical-stage biotech company which specializes in the development of novel therapies to restore
Savara Announces Private Placement of $26.8 Million, With Total Potential Proceeds of $75.0 Million
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that it has entered into a definitive agreement for a private placement with institutional investors to purchase an
Xencor Appoints Dagmar Rosa-Bjorkeson to Board of Directors
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases
Lysogene Announces the Publication of an Article in the Scientific Journal "Molecular Therapy Methods & Clinical Development” Demonstrating the Potential of Its Drug Candidate LYS-SAF302
Regulatory News:
Lysogene (Paris:LYS) (FR0013233475 – LYS), a pioneering Phase 3 biopharmaceutical company specializing in gene therapy targeting central nervous system (CNS) diseases, today
Transgene Announces Financial Calendar for 2020
Regulatory News:
Transgene (Paris:TNG) (Euronext Paris: TNG) today announced its financial reporting dates for 2020:
March 11, 2020: 2019 Fiscal Year Results
May 6, 2020: First Quarter 2020
U.S. FDA Accepts and Grants Priority Review to sNDA for BRAFTOVI® (encorafenib) in Combination with ERBITUX® (cetuximab) (BRAFTOVI Doublet) for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer After Prior Therapy
Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review to the Company’s supplemental New Drug Application (sNDA) for
Pfizer and Mylan Announce Two Future Viatris Board Members
Pfizer Inc. (NYSE: PFE) and Mylan N.V. (NASDAQ: MYL) today announced that Ian Read and James Kilts will join the Viatris board of directors upon completion of the planned combination of Mylan N.V
Xencor Appoints Allen Yang, M.D., Ph.D., as Senior Vice President and Chief Medical Officer
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases
Evotec: Neuer Sanofi-Deal in trockenen Tüchern
Wie heute bekannt gegeben, erweitert Evotec (WKN: 566480) seine Service-Partnerschaft mit Sanofi. Die Aktie dreht nach anfänglichen Käufen ins Minus.
Bisher wurden pulverförmige Substanzen von
Pfizer Invites Public to View and Listen to Webcast of January 28 Conference Call with Analysts
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EST on Tuesday, January 28, 2020. The
Sangamo Highlights Advancements in Genomic Medicine Pipeline and Expanded R&D and Manufacturing Capabilities at R&D Day
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, is hosting an R&D Day today beginning at 8am Eastern Time. During the event, Sangamo executives and scientists plan to provide
XTANDI® (enzalutamide) Approved by U.S. FDA for the Treatment of Metastatic Castration-Sensitive Prostate Cancer
Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) announced today that the U.S. Food and Drug Administration (FDA) has approved a
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on November 1, 2019 and December 2, 2019 the Compensation Committee of Puma’s Board of Directors approved the
NANOBIOTIX Receives the 2019 Prix Galien Award for First-in-Class HENSIFY®
Regulatory News:
NANOBIOTIX (Paris:NANO) (Euronext: NANO - ISIN: FR0011341205 – the “Company”), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today
Bayer: Heimlich, still und leise...
Schaut man sich den Kursverlauf der Aktie von Bayer (WKN: BAY001) näher an, stellt man folgendes fest: Langfristig handelt es sich bei der Aktie um einen Outperformer, mittelfristig um einen
Amarin: Vorzeitige Bescherung durch die FDA!
Am vergangenen Freitag, dem 13. Dezember, war die Aktie von Amarin (WKN: A0NBNG) in den USA den größten Teil des Tages vom Handel ausgesetzt. Grund hierfür war eine bevorstehende, Kurs bewegende
Pfizer Declares First-Quarter 2020 Dividend and Announces Upcoming Investor Day to Highlight Strength of Innovative R&D Pipeline
Pfizer Inc. (NYSE: PFE) announced today that its board of directors declared a 38-cent per share first-quarter 2020 dividend on the company’s common stock, payable March 6, 2020 to holders of the
Initial Clinical Experience Reported from FAP-2286 Named-Patient Use at ICPO Symposium
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that Professor Dr. Richard P. Baum reported his initial independent clinical experience with FAP-2286 in named-patient use at the International